智通财经网·2026-01-30 11:24Core Viewpoint - Fudan Zhangjiang (01349) expects a net loss attributable to shareholders of approximately RMB 120 million to RMB 180 million for the year ending December 31, 2025, compared to a net profit of RMB 39.73 million for 2024 [1] Group 1: Financial Performance - The company anticipates a net loss of approximately RMB 140 million to RMB 200 million when excluding non-recurring gains and losses, compared to a net profit of RMB 5.1452 million for 2024 [1] - The projected net loss reflects a significant decline in financial performance compared to the previous year [1] Group 2: Research and Development - The company is actively advancing its R&D projects, with R&D expenditure rising as a percentage of revenue; approximately RMB 350 million was invested in R&D during the reporting period [2] - The Phase III clinical trial for the FDA018 antibody-drug conjugate for triple-negative breast cancer has exceeded its enrollment target, with over 350 cases enrolled [2] - The company’s subsidiary has been supporting the industrialization of antibody-drug conjugates (ADC), including technology transfer and production process validation [2] Group 3: Market Strategy Adjustments - In 2024, the company's Doxorubicin Liposome Injection was included in the national procurement list, leading to a strategic adjustment in sales for the product "Ribaodu," including a gradual price reduction starting May 1, 2025 [3] - The profit contribution from "Ribaodu" decreased by approximately RMB 100 million compared to the same period last year due to the new procurement rules and market competition [3]